Otsuka Pharmaceutical
Tracked across 4 events · 26 articles · First seen Apr 01, 2026 · Last active Aug 07, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Otsuka Pharmaceutical completed the acquisition of Otsuka Pharmaceutical for $700 million upfront, expanding its portfolio in neuropsychiatric treatments and strengthening its position in central nervous system disorders. This acquisition is expected to accelerate the development of new therapies for serious mental illnesses.
Jun 12, 2026 · 7 articles
Regulatory
Impact: Otsuka's Voyxact is a competitor to TRUTAKNA in the IgAN market.
Jul 07, 2026 · 6 articles
Business
Mironid, a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD), announced on August 5, 2026 that it raised $46 million in a Series B funding round. The round was…
Impact: Otsuka Pharmaceutical, maker of the only approved ADPKD treatment Jynarque, faces potential competition from Mironid's candidate, which may impact its market share.
Aug 05, 2026 · 7 articles
Business
Avatar Robotics, a San Francisco-based startup developing humanoid robots for industrial labor, announced on August 5, 2026 that it raised a $6.5 million Seed round. The round was led by Kevin P. Ryan, with a…
Impact: Mentioned as a past incubation of Kevin P. Ryan, not directly affected by this event.
Aug 05, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Otsuka Pharmaceutical live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard